JPH11509539A - パロキセチン制御放出組成物 - Google Patents
パロキセチン制御放出組成物Info
- Publication number
- JPH11509539A JPH11509539A JP9506325A JP50632597A JPH11509539A JP H11509539 A JPH11509539 A JP H11509539A JP 9506325 A JP9506325 A JP 9506325A JP 50632597 A JP50632597 A JP 50632597A JP H11509539 A JPH11509539 A JP H11509539A
- Authority
- JP
- Japan
- Prior art keywords
- core
- polymer
- release
- deposit
- paroxetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyurethanes Or Polyureas (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.選択的セロトニン再摂取阻害薬(SSRI)を含有する制御放出または遅 延放出製剤。 2.SSRIがパロキセチンまたはその医薬的に許容される塩である請求項1 記載の製剤。 3.腸溶性被覆錠剤もしくはカプセル剤、ワックスまたはポリマー被覆錠剤も しくはカプセル剤または時間−放出マトリックス、またはその組み合わせからな る請求項1または2記載の製剤。 4.SSRIからなる群から選択される活性剤の存在下での、(1)水膨潤可 能で水不溶性の繊維状架橋結合カルボキシ機能性ポリマーであるポリカルボフィ ルカルシウム成分であって、該ポリマーが、(a)少なくとも約80%が少なく とも1つのカルボキシル官能価を含有する複数の反復単位および(b)ポリアル ケニルポリエーテルから実質的に遊離している架橋結合剤約0.05〜約1.5% を含有している(ここで、該パーセンテージは、各々、非重合化反復単位の重量 および架橋結合剤の重量に基づいている)ポリカルボフィルカルシウム成分と、 (2)水との相互作用により形成される反応複合体を含有してなる、高分子制御 放出組成物である請求項1〜3のいずれか1項記載の製剤。 5.a)有効量の活性物質を含有してなり、かつ、所定の幾何学的形を有する デポジット−コア、および(b)該デポジット−コアに適用される支持プラット ホームを含有してなり、ここで、該デポジット−コアが少なくとも活性物質なら びに(1)水または水性液およびゲル化可能な高分子物質と接触して膨潤する高 分子物質であって、ゲル化可能な高分子物質に対する膨潤可能な高分子物質の割 合が1:9〜9:1の範囲である高分子物質および(2)膨潤性およびゲル化性 の両方を有する単一の高分子物質からなる群から選択される少なくとも1つの構 成成分を含有しており、支持プラットホームが弾性支持体であり、デポジット− コアの表面を部分的に覆うようにデポジット−コアに適用され、デポジット−コ アの水和により変化し、水性流体中でゆっくりと可溶性になり、および/または 、 ゆっくりとゲル化可能になる、SSRIである活性物質の制御放出用の系である 請求項1〜3記載のいずれか1項記載の製剤。 6. 必要とする患者に、有効量および/または予防量の請求項1〜5のいず れか1項記載の制御放出または遅延放出製剤を投与することによる障害の治療方 方および/または予防方法。 7.障害の治療薬および/または予防薬の製造における請求項1〜5のいずれ か1項記載の制御放出または遅延放出製剤の使用。 8.所望の割合で成分を混合してなる請求項1〜5のいずれか1項記載の製剤 の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9514842.5 | 1995-07-20 | ||
GBGB9514842.5A GB9514842D0 (en) | 1995-07-20 | 1995-07-20 | Novel formulation |
PCT/EP1996/003252 WO1997003670A1 (en) | 1995-07-20 | 1996-07-19 | Paroxetine controlled release compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006123731A Division JP2006265258A (ja) | 1995-07-20 | 2006-04-27 | パロキセチン制御放出組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11509539A true JPH11509539A (ja) | 1999-08-24 |
JP3922392B2 JP3922392B2 (ja) | 2007-05-30 |
Family
ID=10777960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50632597A Expired - Lifetime JP3922392B2 (ja) | 1995-07-20 | 1996-07-19 | パロキセチン制御放出組成物 |
JP2006123731A Pending JP2006265258A (ja) | 1995-07-20 | 2006-04-27 | パロキセチン制御放出組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006123731A Pending JP2006265258A (ja) | 1995-07-20 | 2006-04-27 | パロキセチン制御放出組成物 |
Country Status (41)
Country | Link |
---|---|
EP (2) | EP1382337A1 (ja) |
JP (2) | JP3922392B2 (ja) |
KR (1) | KR100468351B1 (ja) |
CN (2) | CN1282456C (ja) |
AP (1) | AP1052A (ja) |
AR (1) | AR003463A1 (ja) |
AT (1) | ATE253361T1 (ja) |
AU (1) | AU6659196A (ja) |
BG (1) | BG64076B1 (ja) |
BR (1) | BR9609857A (ja) |
CA (2) | CA2227298C (ja) |
CY (1) | CY2408B1 (ja) |
CZ (1) | CZ294110B6 (ja) |
DE (1) | DE69630603T3 (ja) |
DK (1) | DK0839039T4 (ja) |
DZ (1) | DZ2074A1 (ja) |
EA (2) | EA003775B1 (ja) |
EG (1) | EG23934A (ja) |
ES (1) | ES2208757T5 (ja) |
GB (1) | GB9514842D0 (ja) |
HK (1) | HK1010494A1 (ja) |
HU (1) | HU228853B1 (ja) |
IL (1) | IL122940A0 (ja) |
MA (1) | MA23942A1 (ja) |
MX (1) | MX9800571A (ja) |
MY (1) | MY141373A (ja) |
NO (1) | NO315637B1 (ja) |
NZ (1) | NZ315006A (ja) |
OA (1) | OA10652A (ja) |
PE (1) | PE16098A1 (ja) |
PL (1) | PL184987B1 (ja) |
PT (1) | PT839039E (ja) |
RO (1) | RO119119B1 (ja) |
SI (1) | SI0839039T2 (ja) |
SK (1) | SK284117B6 (ja) |
TR (1) | TR199800077T1 (ja) |
TW (1) | TW464513B (ja) |
UA (1) | UA68328C2 (ja) |
UY (3) | UY24288A1 (ja) |
WO (1) | WO1997003670A1 (ja) |
ZA (1) | ZA966148B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009503057A (ja) * | 2005-08-02 | 2009-01-29 | ルピン・リミテッド | 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物 |
JP2012501960A (ja) * | 2008-09-05 | 2012-01-26 | 大塚製薬株式会社 | 医薬固形製剤 |
JP2013502446A (ja) * | 2009-08-24 | 2013-01-24 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]ピペラジンの新規組成物 |
US10292966B2 (en) | 2003-10-29 | 2019-05-21 | Wyeth Llc | Sustained release pharmaceutical compositions |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
PT994872E (pt) | 1997-06-10 | 2001-09-28 | Synthon Bv | Composto de 4-fenilpiperidina |
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
AU739261B2 (en) | 1997-07-01 | 2001-10-11 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
GB9808479D0 (en) * | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Method of treatment |
CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
US6139875A (en) * | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
DE50011819D1 (de) | 1999-03-12 | 2006-01-12 | Aesica Pharmaceuticals Ltd | Stabile pharmazeutische anwendungsform für paroxetin-anhydrat |
CA2698347A1 (en) * | 1999-05-20 | 2000-11-30 | Elan Pharma International Limited | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
WO2000078290A2 (en) * | 1999-06-22 | 2000-12-28 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a salt of paroxetine |
ES2159260B1 (es) * | 1999-06-22 | 2002-05-01 | Smithkline Beechan Plc | Nueva composicion de metanosulfonato de paroxetina |
ES2162560B1 (es) * | 1999-06-25 | 2002-07-16 | Rodriguez Concepcion Pena | Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia. |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
WO2003013480A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
GB2392385A (en) * | 2002-09-02 | 2004-03-03 | Cipla Ltd | Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone |
EP1734920A2 (en) * | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
WO2005107716A1 (en) * | 2004-03-25 | 2005-11-17 | Cadila Healthcare Limited | Controlled release paroxetine-containing tablets based on a core and a coating |
KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
WO2007132344A2 (en) * | 2006-05-09 | 2007-11-22 | Aurobindo Pharma Limited | Controlled release compositions of an antidepressant agent |
KR100885029B1 (ko) | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
WO2009006299A2 (en) * | 2007-06-29 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Multi-particulate systems |
EP2727915B1 (en) | 2007-09-13 | 2016-04-13 | Concert Pharmaceuticals Inc. | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof |
CN103371982A (zh) * | 2012-04-20 | 2013-10-30 | 王进京 | 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法 |
CN104411368A (zh) * | 2012-07-09 | 2015-03-11 | 荷兰联合利华有限公司 | 光防护性个人护理组合物 |
CN103550182B (zh) * | 2013-10-29 | 2015-04-08 | 吉林省东盟制药有限公司 | 一种肠溶缓释组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8626936D0 (en) * | 1986-11-11 | 1986-12-10 | Ferrosan As | Treatment |
MC2025A1 (fr) * | 1988-04-20 | 1990-04-25 | Asta Pharma Ag | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee |
IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
JPH0436237A (ja) * | 1990-06-01 | 1992-02-06 | Taiho Yakuhin Kogyo Kk | 抗腫瘍性複合製剤 |
EP0497956B1 (en) * | 1990-08-21 | 1996-05-01 | TheraTech, Inc. | Controlled release formulations |
JPH06502854A (ja) * | 1990-11-24 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用 |
AU2154892A (en) * | 1991-05-07 | 1992-12-21 | Dynagen, Inc. | A controlled, sustained release delivery system for treating drug dependency |
JPH05139964A (ja) * | 1991-11-14 | 1993-06-08 | Takada Seiyaku Kk | 塩酸メキシレチン腸溶性製剤 |
PT654263E (pt) * | 1993-11-23 | 2002-06-28 | Euro Celtique Sa | Metodo para a preparacao de uma composicao de libertyacao prolongada |
IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
CA2216934A1 (en) * | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
-
1995
- 1995-07-20 GB GBGB9514842.5A patent/GB9514842D0/en active Pending
-
1996
- 1996-07-17 DZ DZ960118A patent/DZ2074A1/fr active
- 1996-07-18 EG EG68296A patent/EG23934A/xx active
- 1996-07-18 AR ARP960103639A patent/AR003463A1/es not_active Application Discontinuation
- 1996-07-18 MA MA24317A patent/MA23942A1/fr unknown
- 1996-07-18 MY MYPI96002956A patent/MY141373A/en unknown
- 1996-07-19 CA CA002227298A patent/CA2227298C/en not_active Expired - Lifetime
- 1996-07-19 JP JP50632597A patent/JP3922392B2/ja not_active Expired - Lifetime
- 1996-07-19 EA EA199800140A patent/EA003775B1/ru not_active IP Right Cessation
- 1996-07-19 UA UA98010283A patent/UA68328C2/uk unknown
- 1996-07-19 PE PE1996000548A patent/PE16098A1/es not_active IP Right Cessation
- 1996-07-19 CZ CZ1998183A patent/CZ294110B6/cs not_active IP Right Cessation
- 1996-07-19 AU AU66591/96A patent/AU6659196A/en not_active Abandoned
- 1996-07-19 DE DE69630603T patent/DE69630603T3/de not_active Expired - Lifetime
- 1996-07-19 ZA ZA9606148A patent/ZA966148B/xx unknown
- 1996-07-19 PT PT96926388T patent/PT839039E/pt unknown
- 1996-07-19 DK DK96926388T patent/DK0839039T4/da active
- 1996-07-19 TR TR1998/00077T patent/TR199800077T1/xx unknown
- 1996-07-19 RO RO98-00082A patent/RO119119B1/ro unknown
- 1996-07-19 NZ NZ315006A patent/NZ315006A/xx not_active IP Right Cessation
- 1996-07-19 ES ES96926388T patent/ES2208757T5/es not_active Expired - Lifetime
- 1996-07-19 EP EP03078259A patent/EP1382337A1/en not_active Withdrawn
- 1996-07-19 WO PCT/EP1996/003252 patent/WO1997003670A1/en active IP Right Grant
- 1996-07-19 MX MX9800571A patent/MX9800571A/es active IP Right Grant
- 1996-07-19 BR BR9609857A patent/BR9609857A/pt not_active Application Discontinuation
- 1996-07-19 KR KR10-1998-0700380A patent/KR100468351B1/ko not_active IP Right Cessation
- 1996-07-19 EA EA200100022A patent/EA003508B1/ru not_active IP Right Cessation
- 1996-07-19 UY UY24288A patent/UY24288A1/es not_active IP Right Cessation
- 1996-07-19 AP APAP/P/1998/001177A patent/AP1052A/en active
- 1996-07-19 SK SK53-98A patent/SK284117B6/sk not_active IP Right Cessation
- 1996-07-19 EP EP96926388A patent/EP0839039B2/en not_active Expired - Lifetime
- 1996-07-19 CN CNB031490468A patent/CN1282456C/zh not_active Expired - Lifetime
- 1996-07-19 CA CA002445678A patent/CA2445678C/en not_active Expired - Lifetime
- 1996-07-19 PL PL96324553A patent/PL184987B1/pl unknown
- 1996-07-19 IL IL12294096A patent/IL122940A0/xx not_active IP Right Cessation
- 1996-07-19 SI SI9630661T patent/SI0839039T2/sl unknown
- 1996-07-19 AT AT96926388T patent/ATE253361T1/de active
- 1996-07-19 CN CN96196819A patent/CN1117567C/zh not_active Expired - Lifetime
- 1996-07-19 TW TW085108758A patent/TW464513B/zh not_active IP Right Cessation
- 1996-07-19 HU HU9900299A patent/HU228853B1/hu unknown
-
1997
- 1997-01-10 UY UY24436A patent/UY24436A1/es not_active IP Right Cessation
-
1998
- 1998-01-19 NO NO19980240A patent/NO315637B1/no not_active IP Right Cessation
- 1998-01-20 OA OA9800005A patent/OA10652A/en unknown
- 1998-02-17 BG BG102259A patent/BG64076B1/bg unknown
- 1998-11-06 HK HK98111807A patent/HK1010494A1/xx not_active IP Right Cessation
-
2000
- 2000-07-13 UY UY26242A patent/UY26242A1/es not_active Application Discontinuation
-
2004
- 2004-03-15 CY CY0400019A patent/CY2408B1/xx unknown
-
2006
- 2006-04-27 JP JP2006123731A patent/JP2006265258A/ja active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10292966B2 (en) | 2003-10-29 | 2019-05-21 | Wyeth Llc | Sustained release pharmaceutical compositions |
US10463648B2 (en) | 2003-10-29 | 2019-11-05 | Wyeth, Llc | Sustained release pharmaceutical compositions |
US11179369B2 (en) | 2003-10-29 | 2021-11-23 | Wyeth Llc | Sustained release pharmaceutical compositions |
JP2009503057A (ja) * | 2005-08-02 | 2009-01-29 | ルピン・リミテッド | 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物 |
JP2012501960A (ja) * | 2008-09-05 | 2012-01-26 | 大塚製薬株式会社 | 医薬固形製剤 |
JP2015061887A (ja) * | 2008-09-05 | 2015-04-02 | 大塚製薬株式会社 | 医薬固形製剤 |
US9173844B2 (en) | 2008-09-05 | 2015-11-03 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical solid preparation |
JP2013502446A (ja) * | 2009-08-24 | 2013-01-24 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]ピペラジンの新規組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11509539A (ja) | パロキセチン制御放出組成物 | |
US7229640B2 (en) | Paroxetine controlled release compositions | |
CA2521655A1 (en) | Abuse-resistant oral dosage forms and method of use thereof | |
AU698784B2 (en) | Alkalinizing potassium salt controlled release preparations | |
JP2001523704A (ja) | α−グルコシダーゼ阻害剤を含んで成る持続放出性製剤 | |
JP2002508003A (ja) | 新規な組成物 | |
AU740749B2 (en) | Method of treatment | |
EP1448173A2 (en) | A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride | |
AU748804B2 (en) | Paroxetine controlled release compositions | |
Dementia et al. | TOTAL 100.0 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041019 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050418 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060131 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060427 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060803 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3922392 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100302 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110302 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120302 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130302 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140302 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140302 Year of fee payment: 7 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |